glp 1 agonist with dpp 4 inhibitor GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician? Prescribing pearls: A guide to

MOTS-c Strength: 10 mg Mitochondrial-derived peptide A performance and energy-oriented peptide option frequently associated with metabolic resilience support

They come with a US Boxed Warning of a risk of thyroid C-cell tumors and medullary thyroid carcinoma and are contraindicated in patients with multiple endocrine neoplasia syndrome type 2

Lancet 382:339352 Thomas MC, Cooper ME, Zimmet P (2016) Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease

Compounded Medication Notice

The role of GLP-1 RAs in enhancing patient outcomes, particularly in those with type 2 diabetes, is well-established, and their use for weight loss has gained considerable attention in the medical community as an effective adjunct therapy (Nathan et al

These results are promising, but more research is also needed to find out why GLP-1s may reduce death from all causes in this group